Guardant Health (GH) Q1 Revenue Jumps 48% to $301.7M on Strong Screening Growth

Guardant Health Inc. (NASDAQ:GH) is one of the best large cap stocks to buy under $100. On May 7, Guardant Health reported Q1 2026 total revenue of $301.7 million, a 48% increase year-over-year driven by strong performance across its portfolio. Oncology revenue grew 36% to $205.0 million, Biopharma & Data revenue rose 17% to $53.0 million, and Screening revenue surged over 600% to $41.6 million. The company achieved a GAAP gross margin of 65% and a non-GAAP gross margin of 66%.

Operating expenses rose due to commercial infrastructure expansion and marketing, resulting in a GAAP net loss of $112.1 million ($0.85 per share) and a non-GAAP net loss of $58.7 million ($0.45 per share). The adjusted EBITDA loss was $58.9 million, while free cash flow stood at negative $71.2 million. Guardant Health Inc. (NASDAQ:GH) closed the quarter with $1.2 billion in cash, cash equivalents, restricted cash, and marketable securities.

Key operational milestones included expanding Guardant360 Tissue capabilities, securing FDA companion diagnostic approval for Guardant360 CDx, and partnering with Quest and Manulife. Driven by this momentum, the company raised its full-year 2026 revenue guidance to a range of $1.30 to $1.32 billion, representing 32% to 34% growth over the prior year.

Guardant Health Inc. (NASDAQ:GH) is a precision oncology firm.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.